Abstract
Human 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), a potential target in breast cancer prevention and therapy, was extracted from human placenta and immobilized on nonporous silica (∼5 μm) with a covalent method for the first time. The optimum initial enzyme concentration and immobilization time during the immobilization process were 0.42 mg mL−1 and 12 h, repectively. The binding was confirmed by scanning electron microscope (SEM) and infrared spectroscopy (FT-IR). It could improve the pH, thermal and storage stability compared to free enzyme. Moreover, the immobilized enzyme could be reused at least four times. A screening method based on it coupled with liquid chromatography–time-of-flight mass spectrometer (LC-TOF/MS) was established, and the half-maximal inhibitory concentration (IC 50) of apigenin for the immobilized enzyme was 291 nM. Subsequently, 10 natural products were evaluated leading to inhibition of the activity of 17β-HSD1 at the concentration of 25 μM, and six of them inhibit the activity over 50%.
Similar content being viewed by others
References
Yan, L., Liu, J., Liu, X., Xing, K., Yun, W., Li, F., & Yao, L. (2006). Resveratrol-induced cell inhibition of growth and apoptosis in MCF7 human breast cancer cells are associated with modulation of phosphorylated akt and caspase-9. Applied Biochemistry & Biotechnology, 135, 181–192.
Fournier, D., Poirier, D., Mazumdar, M., & Lin, S. X. (2008). Design and synthesis of bisubstrate inhibitors of type 1 17β-hydroxysteroid dehydrogenase: overview and perspectives. European Journal of Medicinal Chemistry, 43, 2298–2306.
Aka, J. A., Mazumdar, M., Chen, C. Q., Poirier, D., & Lin, S. X. (2010). 17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production. Molecular Endocrinology, 24, 832–845.
Kasai, T., Shozu, M., Murakami, K., Segawa, T., Shinohara, K., Nomura, K., & Inoue, M. (2004). Increased expression of type I 17beta-hydroxysteroid dehydrogenase enhances in situ production of estradiol in uterine leiomyoma. Journal of Clinical Endocrinology & Metabolism, 89, 5661–5668.
Jarabak, J., Adams, J. A., Williamsashman, H. G., & Talalay, P. (1962). Purification of a 17beta-hydroxysteroid dehydrogenase of human placenta and studies on its transhydrogenase function. Journal of Biological Chemistry, 237, 345–357.
Adams, J. A., Jarabak, J., & Talalay, P. (1962). The steroid specificity of the 17β-hydroxysteroid dehydrogenase of human placenta. Journal of Biological Chemistry, 237, 3069–3073.
Langer, L. J., & Engel, L. L. (1958). Human placental estradiol-17 beta dehydrogenase. I. Concentration, characterization and assay. Journal of Biological Chemistry, 233, 583–588.
Zhu, S. J., Li, Y., Li, H., Wang, Y. L., Xiao, Z. J., Vihko, P., & Piao, Y. S. (2002). Retinoic acids promote the action of aromatase and 17beta-hydroxysteroid dehydrogenase type 1 on the biosynthesis of 17beta-estradiol in placental cells. Journal of Endocrinology, 172, 31–43.
Breton, R., Housset, D., Mazza, C., & Fontecilla-Camps, J. C. (1996). The structure of a complex of human 17β-hydroxysteroid dehydrogenase with estradiol and NADP + identifies two principal targets for the design of inhibitors. Structure, 4, 905–915.
Shi, R., & Lin, S. X. (2004). Cofactor hydrogen bonding onto the protein main chain is conserved in the short chain dehydrogenase/reductase family and contributes to nicotinamide orientation. Journal of Biological Chemistry, 279, 16778–16785.
Puranen, T., Poutanen, M., Ghosh, D., Vihko, R., & Vihko, P. (1997). Origin of substrate specificity of human and rat 17β-hydroxysteroid dehydrogenase type 1, using chimeric enzymes and site-directed substitutions 1. Endocrinology, 138, 3532–3539.
Lin, S.-X., Shi, R., Qiu, W., Azzi, A., Zhu, D.-W., Al Dabbagh, H., & Zhou, M. (2006). Structural basis of the multispecificity demonstrated by 17β-hydroxysteroid dehydrogenase types 1 and 5. Molecular & Cellular Endocrinology, 248, 38–46.
Fournier, D., Poirier, D., Mazumdar, M., & Lin, S. X. (2008). Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives. European Journal of Medicinal Chemistry, 43, 2298–2306.
Bail, J. C. L., Champavier, Y., Chulia, A. J., & Habrioux, G. (2000). Effects of phytoestrogens on aromatase, 3β and 17β-hydroxysteroid dehydrogenase activities and human breast cancer cells. Life Sciences, 66, 1281–1291.
Poirier, D. (2003). Inhibitors of 17β-hydroxysteroid dehydrogenases. Current Medicinal Chemistry, 10, 453–477.
Michiels, P. J., & Cstephan, L. (2009). Ligand-based NMR spectra demonstrate an additional phytoestrogen binding site for 17beta-hydroxysteroid dehydrogenase type 1. Journal of Steroid Biochemistry & Molecular Biology, 117, 93–98.
Deluca, D., Krazeisen, A., Breitling, R., Prehn, C., Möller, G., & Adamski, J. (2005). Inhibition of 17beta-hydroxysteroid dehydrogenases by phytoestrogens: comparison with other steroid metabolizing enzymes. Journal of Steroid Biochemistry & Molecular Biology, 93, 285–292.
Starčević, Š., Turk, S., Brus, B., Cesar, J., Rižner, T. L., & Gobec, S. (2011). Discovery of highly potent, nonsteroidal 17β-hydroxysteroid dehydrogenase type 1 inhibitors by virtual high-throughput screening. The Journal of Steroid Biochemistry and Molecular Biology, 127, 255–261.
Zanin, G. M., & Moraes, F. F. D. (1998). Thermal stability and energy of deactivation of free and immobilized amyloglucosidase in the saccharification of liquefied cassava starch. Applied Biochemistry & Biotechnology, 70-72, 383–394.
Villee, C. A., & Gordon, E. E. (1955). Further studies on the action of estradiol in vitro. Journal of Biological Chemistry, 216, 203–214.
Kruger, N. J. (1994) In Basic protein and peptide protocols (pp. 9–15) Springer.
Mohamad, N. R., Marzuki, N. H., Buang, N. A., Huyop, F., & Wahab, R. A. (2015). An overview of technologies for immobilization of enzymes and surface analysis techniques for immobilized enzymes. Biotechnology Biotechnological Equipment, 29, 205–220.
Petkova, G. A., Záruba, K., & Král, V. (2012). Synthesis of silica particles and their application as supports for alcohol dehydrogenases and cofactor immobilizations: conformational changes that lead to switch in enzyme stereoselectivity. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 1824, 792–801.
Shen, H., Pan, S., Zhang, Y., Huang, X., & Gong, H. (2012). A new insight on the adsorption mechanism of amino-functionalized nano-Fe 3 O 4 magnetic polymers in Cu (II), Cr (VI) co-existing water system. Chemical Engineering Journal, 183, 180–191.
Chang, Q., & Tang, H. (2014). Immobilization of horseradish peroxidase on NH2-modified magnetic Fe3O4/SiO2 particles and its application in removal of 2, 4-dichlorophenol. Molecules, 19, 15768–15782.
Klein, M. P., Nunes, M. R., Rodrigues, R. C., Benvenutti, E. V., Costa, T. M., Hertz, P. F., & Ninow, J. L. (2012). Effect of the support size on the properties of β-galactosidase immobilized on chitosan: advantages and disadvantages of macro and nanoparticles. Biomacromolecules, 13, 2456–2464.
Le Bail, J., Laroche, T., Marre-Fournier, F., & Habrioux, G. (1998). Aromatase and 17β-hydroxysteroid dehydrogenase inhibition by flavonoids. Cancer Letters, 133, 101–106.
Acknowledgements
The authors gratefully acknowledge the financial support for this work from the Natural Science Foundation of Jiangsu Province (No. BK20130654) and the National Natural Science Foundation of PR China (No. 81402900).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Bai, Y., Zhou, WD., Mu, XM. et al. Covalent Immobilization of Human Placental 17β-Hydroxysteroid Dehydrogenase Type 1 onto Glutaraldehyde Activated Silica Coupled with LC-TOF/MS for Anti-Cancer Drug Screening Applications. Appl Biochem Biotechnol 182, 482–494 (2017). https://doi.org/10.1007/s12010-016-2339-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12010-016-2339-6